Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers

Duruisseaux, M.; Antoine, Martine; Rabbe, Nathalie; Rodenas, Anita; Leer-Florin, Anne Mc; Lacave, Roger; Poulot, Virginie; Duchêne, Bélinda; Seuningen, Isabelle Van; Cadranel, Jacques; Wislez, Marie

doi:10.1016/j.lungcan.2017.05.007

Cited by 29 publications

(28 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported, non‐TRU‐type adenocarcinomas, such as IMA, mostly expressed MUC5AC and MUC5B, whereas TRU‐type ones did not . However, in our study, most of the EGFR ‐mutated mucinous adenocarcinomas expressed only MUC5B.…”

Section: Discussionsupporting

confidence: 77%

“…The expression patterns of MUC1 and MUC5AC were different between EGFR ‐mutated and ALK ‐fused adenocarcinomas . Furthermore, MUC1, MUC5AC, MUC5B and MUC6 expressions differed between IMA and lepidic adenocarcinoma as well as according to the TTF‐1/HNF‐4a status . However, the mucin profiles of EGFR ‐mutated mucinous adenocarcinoma remain unclear.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Mucinous lung adenocarcinoma, particularly referring to EGFR‐mutated mucinous adenocarcinoma

Wakejima

Inamura

Ninomiya

et al. 2019

Pathology International

View full text Add to dashboard Cite

EGFR-mutated adenocarcinoma. Among 1159 surgically resected invasive adenocarcinomas, 189 mucinous adenocarcinomas (16%) were identified. Among these, 20%, 34% and 9.5% were EGFR mutated, KRAS mutated and ALK rearranged, respectively. Compared with EGFR-mutated nonmucinous adenocarcinoma, EGFR-mutated mucinous adenocarcinoma had no female predominance, lower grades of histological differentiation and lower TTF-1 and higher HNF-4a expressions. Moreover, for the first time, we indicated that mucin production was an independent prognostic factor for EGFR-mutated adenocarcinomas and the mucin-staining pattern of negative MUC5AC and positive MUC5B was characteristic in these adenocarcinomas. We suggest that EGFRmutated mucinous adenocarcinoma has a different tumorigenic pathway than nonmucinous EGFR-mutated adenocarcinoma. K E Y W O R D S adenocarcinoma, EGFR mutation, HNF-4a, KRAS mutation, lung, MUC1, MUC5B, mucin, TTF-1

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Introductionmentioning

confidence: 98%

Mucinous lung adenocarcinoma, particularly referring to EGFR‐mutated mucinous adenocarcinoma

Wakejima

Inamura

Ninomiya

et al. 2019

Pathology International

View full text Add to dashboard Cite

show abstract

“…Given that the differentiation of lung adenocarcinomas with mucinous features (pulmonary mucinous adenocarcinomas) from metastatic lesions is often challenging on a morphologic basis alone, multiple groups have studied the role of IHC in this context. In particular, distinguishing a metastasis from a pancreatic primary from invasive mucinous adenocarcinoma of the lung is far more challenging, given the similar immunoprofiles (focal caudal type homeobox 2 (CDX2) and cytokeratin 20 [ Table 8]) [140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155][156][157][158][159]161 ; furthermore, a lepidic growth pattern, which is characteristic of invasive mucinous adenocarcinoma (Fig. 12), is also often identified in pancreatic ductal adenocarcinoma metastatic to the lung (Fig.…”

Section: Salivary Gland-type Tumorsmentioning

confidence: 99%

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Yatabe

Đačić

Borczuk

et al. 2019

Journal of Thoracic Oncology

241

221

View full text Add to dashboard Cite

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' treatment of choice is directly linked to histologic subtypes of non-small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

show abstract

“…Recently, it has been demonstrated that MUC5B serves as a marker for the non-terminal respiratory unit (TRU) subtype and the invasive mucinous adenocarcinomas associated with KRAS mutations [ 60 , 61 ]. As mentioned above, MUC5B polymorphism is associated with pulmonary fibrosis [ 21 , 22 , 23 ], and presumably, mucin 5B is overexpressed in IPF lung tissue.…”

Section: Genomic Features Of Lung Cancer That Occurs In Pulmonary mentioning

confidence: 99%

The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis

Saito

Horie

Micke

et al. 2018

IJMS

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown etiology and dismal prognosis. IPF patients are known to have an increased risk of lung cancer and careful decision-making is required for the treatment of lung cancer associated with IPF. Transforming growth factor (TGF)-β signaling plays a central role in tissue fibrosis and tumorigenesis. TGF-β-mediated pathological changes that occur in IPF lung tissue may promote the process of field cancerization and provide the microenvironment favorable to cancer initiation and progression. This review summarizes the current knowledge related to IPF pathogenesis and explores the molecular mechanisms that underlie the occurrence of lung cancer in the background of IPF, with an emphasis on the multifaceted effects of TGF-β signaling.

show abstract

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers

Abstract: LPA and IMA exhibit specific mucin expression profiles, with MUC1 being associated with LPA, while MUC5B, MUC5AC, and MUC6 were associated with IMA. Hnf4α expression and EGFR and KRAS mutations may play a role in mucin expression profiles of these lung adenocarcinoma subtypes.

Cited by 29 publications

References 51 publications

Mucinous lung adenocarcinoma, particularly referring to EGFR‐mutated mucinous adenocarcinoma

Mucinous lung adenocarcinoma, particularly referring to EGFR‐mutated mucinous adenocarcinoma

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About